Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study (Blood Cancer Journal, (2023), 13, 1, (72), 10.1038/s41408-023-00797-8)

Thomas Martin; Meletios Athanasios Dimopoulos; Joseph Mikhael; Kwee Yong; Marcelo Capra; Thierry Facon; Roman Hajek; Ivan Špička; Ross Baker; Kihyun Kim; Gracia Martinez; Chang Ki Min; Ludek Pour; Xavier Leleu; Albert Oriol; Youngil Koh; Kenshi Suzuki; France Casca; Sandrine Macé; Marie Laure Risse; Philippe Moreau

doi:10.1038/s41408-023-00923-6

Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study (Blood Cancer Journal, (2023), 13, 1, (72), 10.1038/s41408-023-00797-8)

Thomas Martin, Meletios Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, Gracia Martinez, Chang Ki Min, Ludek Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, France Casca, Sandrine Macé, Marie Laure RissePhilippe Moreau

Division of Hematology

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Abstract

Correction to: Blood Cancer Journal, published online 09 May 2023 In the sentence beginning ‘Isa is approved in multiple countries..’ in ‘Introduction’, the term ‘treatment lines’ should have read ‘therapies’. The full text is as follows. Isa is approved in multiple countries in combination with pomalidomide and low-dose dexamethasone for patients with RRMM after ≥2 prior therapies, based on the results of the randomized Phase 3 ICARIA-MM study. The original article has been corrected.

Original language	English
Article number	152
Journal	Blood Cancer Journal
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41408-023-00923-6
State	Published - Dec 2023

Bibliographical note

Publisher Copyright:
© 2023, Springer Nature Limited.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41408-023-00923-6

Fingerprint

Dive into the research topics of 'Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study (Blood Cancer Journal, (2023), 13, 1, (72), 10.1038/s41408-023-00797-8)'. Together they form a unique fingerprint.

Cite this

Martin, T., Dimopoulos, M. A., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Baker, R., Kim, K., Martinez, G., Min, C. K., Pour, L., Leleu, X., Oriol, A., Koh, Y., Suzuki, K., Casca, F., Macé, S., ... Moreau, P. (2023). Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study (Blood Cancer Journal, (2023), 13, 1, (72), 10.1038/s41408-023-00797-8). Blood Cancer Journal, 13(1), Article 152. https://doi.org/10.1038/s41408-023-00923-6

@article{f513a6931cf94f40b949ef33492c9d7c,

title = "Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study (Blood Cancer Journal, (2023), 13, 1, (72), 10.1038/s41408-023-00797-8)",

abstract = "Correction to: Blood Cancer Journal, published online 09 May 2023 In the sentence beginning {\textquoteleft}Isa is approved in multiple countries..{\textquoteright} in {\textquoteleft}Introduction{\textquoteright}, the term {\textquoteleft}treatment lines{\textquoteright} should have read {\textquoteleft}therapies{\textquoteright}. The full text is as follows. Isa is approved in multiple countries in combination with pomalidomide and low-dose dexamethasone for patients with RRMM after ≥2 prior therapies, based on the results of the randomized Phase 3 ICARIA-MM study. The original article has been corrected.",

author = "Thomas Martin and Dimopoulos, {Meletios Athanasios} and Joseph Mikhael and Kwee Yong and Marcelo Capra and Thierry Facon and Roman Hajek and Ivan {\v S}pi{\v c}ka and Ross Baker and Kihyun Kim and Gracia Martinez and Min, {Chang Ki} and Ludek Pour and Xavier Leleu and Albert Oriol and Youngil Koh and Kenshi Suzuki and France Casca and Sandrine Mac{\'e} and Risse, {Marie Laure} and Philippe Moreau",

note = "Publisher Copyright: {\textcopyright} 2023, Springer Nature Limited.",

year = "2023",

month = dec,

doi = "10.1038/s41408-023-00923-6",

language = "English",

volume = "13",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "1",

}

Martin, T, Dimopoulos, MA, Mikhael, J, Yong, K, Capra, M, Facon, T, Hajek, R, Špička, I, Baker, R, Kim, K, Martinez, G, Min, CK, Pour, L, Leleu, X, Oriol, A, Koh, Y, Suzuki, K, Casca, F, Macé, S, Risse, ML & Moreau, P 2023, 'Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study (Blood Cancer Journal, (2023), 13, 1, (72), 10.1038/s41408-023-00797-8)', Blood Cancer Journal, vol. 13, no. 1, 152. https://doi.org/10.1038/s41408-023-00923-6

Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study (Blood Cancer Journal, (2023), 13, 1, (72), 10.1038/s41408-023-00797-8). / Martin, Thomas; Dimopoulos, Meletios Athanasios; Mikhael, Joseph et al.
In: Blood Cancer Journal, Vol. 13, No. 1, 152, 12.2023.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction

T2 - Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study (Blood Cancer Journal, (2023), 13, 1, (72), 10.1038/s41408-023-00797-8)

AU - Martin, Thomas

AU - Dimopoulos, Meletios Athanasios

AU - Mikhael, Joseph

AU - Yong, Kwee

AU - Capra, Marcelo

AU - Facon, Thierry

AU - Hajek, Roman

AU - Špička, Ivan

AU - Baker, Ross

AU - Kim, Kihyun

AU - Martinez, Gracia

AU - Min, Chang Ki

AU - Pour, Ludek

AU - Leleu, Xavier

AU - Oriol, Albert

AU - Koh, Youngil

AU - Suzuki, Kenshi

AU - Casca, France

AU - Macé, Sandrine

AU - Risse, Marie Laure

AU - Moreau, Philippe

PY - 2023/12

Y1 - 2023/12

N2 - Correction to: Blood Cancer Journal, published online 09 May 2023 In the sentence beginning ‘Isa is approved in multiple countries..’ in ‘Introduction’, the term ‘treatment lines’ should have read ‘therapies’. The full text is as follows. Isa is approved in multiple countries in combination with pomalidomide and low-dose dexamethasone for patients with RRMM after ≥2 prior therapies, based on the results of the randomized Phase 3 ICARIA-MM study. The original article has been corrected.

AB - Correction to: Blood Cancer Journal, published online 09 May 2023 In the sentence beginning ‘Isa is approved in multiple countries..’ in ‘Introduction’, the term ‘treatment lines’ should have read ‘therapies’. The full text is as follows. Isa is approved in multiple countries in combination with pomalidomide and low-dose dexamethasone for patients with RRMM after ≥2 prior therapies, based on the results of the randomized Phase 3 ICARIA-MM study. The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85172403466&partnerID=8YFLogxK

U2 - 10.1038/s41408-023-00923-6

DO - 10.1038/s41408-023-00923-6

M3 - Comment/debate

C2 - 37752114

AN - SCOPUS:85172403466

SN - 2044-5385

VL - 13

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 1

M1 - 152

ER -

Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study (Blood Cancer Journal, (2023), 13, 1, (72), 10.1038/s41408-023-00797-8)

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this